Cumberland Pharmaceuticals (CPIX) Reports Q4 EPS of $0.10
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Cumberland Pharma (CPIX) Announces Achieving Several Clinical, Regulatory Milestones; Provides Update
March 4, 2015 6:39 AM ESTCumberland Pharmaceuticals (NASDAQ: CPIX) announced achievement of several clinical and regulatory milestones. These developments include top-line results from the Company's Hepatoren Phase II study, submission of a supplemental New Drug Application (sNDA) with pediatric data for Caldolor and initiation of patient enrollment in the Boxaban Phase II clinical trial.
"The sNDA for Caldolor represents a key milestone following the conclusion of a series of important Phase IV studies for the product. We look forward to working with the FDA with the goal of adding pediatric information to the Caldolor label," said A.J. Kazimi,... More
